Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients.

Sofia VerkhovskaiaFrancesca Romana Di PietroSimona MastroeniMaria Luigia CarboneDamiano AbeniRoberto MoreseFrancesca Maria MorelliStefania D'AtriPaolo MarchettiFederica De GalitiisCristina Maria FaillaCristina Fortes

Published in: Journal of cancer research and clinical oncology (2021)

Our findings indicate that onset of vitiligo-like leukoderma during melanoma treatment could be a marker of favorable outcome in patients treated with immune checkpoint inhibitors.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
skin cancer
patient reported outcomes
replacement therapy